Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania

BACKGROUND: Brexpiprazole is a dopamine/serotonin receptor partial agonist (D(2), 5-HT(1A)) and antagonist (5-HT(2A)) approved for treatment of schizophrenia and major depressive disorder (adjunct to antidepressants). AIMS: This study aimed to investigate brexpiprazole as monotherapy in acute mania...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieta, Eduard, Sachs, Gary, Chang, Denise, Hellsten, Johan, Brewer, Claudette, Peters-Strickland, Timothy, Hefting, Nanco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366183/
https://www.ncbi.nlm.nih.gov/pubmed/33691517
http://dx.doi.org/10.1177/0269881120985102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366183/
https://www.ncbi.nlm.nih.gov/pubmed/33691517
http://dx.doi.org/10.1177/0269881120985102

Ejemplares similares